1052532-15-6

Basic information

• Product Name: SBE 13 hydrochloride
• Synonyms: SBE 13 hydrochloride;N-(4-((6-chloropyridin-3-yl)Methoxy)-3-Methoxybenzyl)-2-(3,4-diMethoxyphenyl)ethanaMine hydrochloride;SBE-13 HCl;N-(4-((6-Chloro-3-pyridinyl)methoxy)-3-methoxybenzyl)-N-(2-(3,4-dimethoxyphenyl)ethyl)amine;N-[[4-[(6-Chloro-3-pyridinyl)methoxy]-3-methoxyphenyl]methyl]-3,4-dimethoxy-benzeneethanamine hydrochloride
• CAS NO: 1052532-15-6
• Molecular Formula: C24H28Cl2N2O4
• Molecular Weight: 479.39612
• Product Categories: Inhibitors
• Mol File: 1052532-15-6.mol
• Article Data: 0

Chemical Properties

• Appearance: white to tan/
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥17mg/mL
• CAS DataBase Reference: SBE 13 hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: SBE 13 hydrochloride(1052532-15-6)
• EPA Substance Registry System: SBE 13 hydrochloride(1052532-15-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 1052532-15-6(Hazardous Substances Data)

Usage

Description

SBE 13 hydrochloride is a potent and selective inhibitor of polo-like kinase 1 (Plk1), a protein that plays a crucial role in cell division and regulation. With an IC50 value of 0.2 nM, it targets the inactive conformation of the enzyme, making it a highly effective compound. SBE 13 hydrochloride demonstrates no activity against aurora A kinase and shows less effectiveness in inhibiting Plk2 (IC50 > 66 μM) and Plk3 (IC50 = 875 nM). SBE 13 hydrochloride is known to induce cell cycle arrest, reduce cell proliferation (EC50 = 5-60 μM), and induce apoptosis in a broad range of human cancer cell lines.

Uses

Used in Pharmaceutical Industry:
SBE 13 hydrochloride is used as a selective inhibitor for [targeting Plk1 in cancer treatment] because of its high potency and selectivity in inhibiting Plk1, which is involved in cell division and regulation. This makes it a promising candidate for the development of anti-cancer drugs.
Used in Cancer Research:
SBE 13 hydrochloride is used as a research tool for [studying the role of Plk1 in cell division and cancer progression] due to its ability to induce cell cycle arrest, reduce cell proliferation, and induce apoptosis in various human cancer cell lines. This helps researchers understand the mechanisms of cancer development and identify potential therapeutic targets.
Used in Drug Development:
SBE 13 hydrochloride is used as a lead compound for [developing new anti-cancer drugs] as its high potency and selectivity make it an attractive starting point for designing and optimizing novel therapeutic agents targeting Plk1 in cancer treatment.
Used in Drug Delivery Systems:
SBE 13 hydrochloride can be used as an active pharmaceutical ingredient for [developing targeted drug delivery systems] to improve the bioavailability, delivery, and therapeutic outcomes of Plk1 inhibitors in cancer treatment. This may involve the use of various organic and metallic nanoparticles as carriers for SBE 13 hydrochloride, aiming to enhance its efficacy and reduce potential side effects.

in vitro

to determine its ability to induce cell death in cancer cells, we applied kinase assays, western blot analyses, facs can analyses, caspase assays and immunofluorescence studies. we detected decreased cell proliferation, delayed progression through the cell cycle in lower sbe13 concentrations, a g2/m arrest using higher sbe13 concentrations followed by apoptosis, and abnormal mitotic figures. notably, sbe13 did not influence activity of other kinases (plk2, plk3, aurora a), indicating the selectivity of this type ii plk1 inhibitor [1].